Overview of secondary liver cancer care pathways, key treatment steps, and the situations where dendritic cell treatment may be discussed as a selected option.

The current research frontier in blastic plasmacytoid dendritic cell neoplasm (BPDCN) is moving toward combination triplet therapies. Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, explores ...

Potential autoimmune diseases therapies that target dendritic cells aim to either inhibit immunogenic dendritic cell functions or support their tolerogenic potential (Figure 2). Most strategies ...

CD123 is universally and highly expressed on BPDCN cells. Because CD123 expression is significantly lower on normal hematopoietic stem cells, it provides a distinct "therapeutic window," allowing for ...

Dendritic cells (DCs) are increasingly recognized as important contributors to sepsis-associated immune dysfunction. As professional antigen-presenting cells, they bridge innate sensing and durable ...

Dendritic cells (DCs) are among the first immune sentinels to detect viruses, bacteria, or other challenges. These specialized messengers alert T cells while orchestrating either a measured calm or a ...

The immune system has evolved to mount immune responses against foreign pathogens and to remain silent against self-antigens. A balance between immunity and tolerance is required as any disturbance ...

Sepsis remains a major challenge in modern medicine, claiming millions of lives each year. For decades, clinical management ...

Follicular dendritic cell sarcoma (FDCS) is an uncommon neoplasm originating from the accessory cells of the immune system that ordinarily play a crucial role in antigen presentation and the ...